On The Pen GLP-1 News
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.
On The Pen GLP-1 News
Latest Episodes
Cheap Zepbound Incoming for Medicare, But CMS Just Issued a Catch
On this episode of the podcast, host Dave Knapp breaks down the latest updates on potential GLP-1 receptor agonists coverage for people on Medicare living with obesity. With new guidance released by the Centers for Medicare & Medicaid Servi...
Gray Market GLP-1 Is Booming Branded Access is Broken
Episode Summary (Short Version):This week on On The Pen, Dave breaks down the rapid changes reshaping GLP-1 access — from new federal reforms targeting PBMs and possible FDA limits on compounded semaglutide, to Walgreens ...
NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?
This episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.
Fan Mail
Dave I’ve been following you for about a year now. I just want to thank you for all you do and the true outgoing concern that you show for all of us who struggle with this journey. Thank you especially for the courage to share your own journey with us. I just listened to the most recent podcast with Dr. Nadolsky. I completely understand your difficulty with the decision to have surgery. I’ve been overweight/obese for over 30 years and just could never convince myself that the surgery was a good idea for me. It is a HUGE decision, not just because it is a surgery but also because of the changes it will require in your life. So God bless you for all that you do and your courage to do it to help so many others!
Monroe, Louisiana
